Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00348933 · ClinicalTrials.gov registry record · NA
Dietary Supplements for the Treatment of Angelman Syndrome
A NA study of Nervous System Diseases and Angelman Syndrome, sponsored by University of California, San Diego.
- Completed
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 4
- Study locations
NCT00348933: Completed NA study of Nervous System Diseases and Angelman Syndrome, sponsored by University of California, San Diego.
NCT00348933 is a NA study of Nervous System Diseases and Angelman Syndrome that has completed, run by University of California, San Diego. The registered enrollment target is 90 participants, below the 320-participant average among 23 other Nervous System Diseases trials with a reported enrollment target (72% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00348933, a NA study of Nervous System Diseases and Angelman Syndrome, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 4
- Study locations
Study Summary
Angelman syndrome (AS) is a complex genetic disorder that affects the nervous system. The purpose of this study is to determine the effectiveness of certain dietary supplements in treating the symptoms of AS.
Primary Outcome
Primary: Bayley Scales of Infant Development measures Mental Developmental Index standard scores 0 (least skilled) - 100 (most skilled) Psychomotor Developmental Index standard scores 0 (least skilled - 10 (most skilled) Vineland Adaptive Behavior Scales (VABS), Communication standard scores 0 (least skilled) - 100 (most skilled) Daily Living Skills standard scores 0 (least skilled) - 100 (most skilled) Socialization standard scores 0 (least skilled) - 100 (most skilled) Motor Skills standard s
Conditions Studied
Interventions
- DRUG Betaine
- DRUG Creatine
- DRUG Metafolin
- DRUG Vitamin B12
Study Locations (4)
California
- Rady Children's Hospital San Diego - San Diego
Massachusetts
- Children's Hospital Boston - Boston
South Carolina
- Greenwood Genetics Center - Greenwood
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2006-07 |
| Est. Completion | 2010-02 |
| Phase | NA |
What the finished NCT00348933 record still lists
NCT00348933 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 320-participant average among 23 other Nervous System Diseases trials with a reported enrollment target (72% lower).
The record links to 2 conditions, with Nervous System Diseases appearing as the primary indexed condition, and to 4 interventions - of which Betaine is the first listed.
NCT00348933 reports a single indexed study location in California, Massachusetts, South Carolina.
Frequently Asked Questions
What is clinical trial NCT00348933 about?
NCT00348933 is a clinical study titled "Dietary Supplements for the Treatment of Angelman Syndrome". Angelman syndrome (AS) is a complex genetic disorder that affects the nervous system. The purpose of this study is to determine the effectiveness of certain dietary supplements in treating the symptoms of AS.
What is the current status of trial NCT00348933?
This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2006-07. Estimated completion is 2010-02.
What conditions does trial NCT00348933 study?
This clinical trial studies the following conditions: Nervous System Diseases, Angelman Syndrome.
What interventions are being tested in trial NCT00348933?
The interventions under investigation include: Betaine (DRUG), Creatine (DRUG), Metafolin (DRUG), Vitamin B12 (DRUG).
Who is sponsoring clinical trial NCT00348933?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00348933 being conducted?
This trial has 4 study locations across California, Massachusetts, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nervous System Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00348933's enrollment target sits among peer trials
90 11th of 23 higher than 12 of 23 other Nervous System Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nervous System Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
-
The Effect of Transcutaneous Stimulation on Blood Pressure in Spinal Cord Injury (SCI)
RECRUITING · NA
-
Spinal Cord Transcutaneous Stimulation Effect on Blood Pressure in Acute Spinal Cord Injury (SCI)
RECRUITING · NA
-
Neurologic Stem Cell Treatment Study
RECRUITING · NA
-
Brain Connections for Arm Movement After Stroke
RECRUITING · NA
-
Tai Chi Effects on Chronic Insomnia in Breast Cancer Survivors: Immune Mechanisms
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia